Introduction
Approximately 25% of patients with pituitary adenomas have no clinical or biochemical evidence for excess hormone secretion and are classified as having null cell or nonfunctioning adenomas. To characterize the cell type of these tumors, we analyzed pituitary hormone gene expression in clinically nonfunctioning pituitary adenomas using specific oligonucleotide probes for the messenger (m)RNAs encoding growth hormone, prolactin, ACIH, and the glycoprotein hormone subunits, a, luteinizing hormone (LH)/3, follicle-stimulating hormone (FSH)/3, and thyroid-stimulating hormone (TSH), 8 . Expression of one or more of the anterior pituitary hormone genes was found in 2A/4 (86%) of the patients with clinically classified nonfunctioning adenomas. Expression of one or more of the glycoprotein hormone genes (a, LHfl, FSH,6, TSHft) was identified most commonly (79%) with expression of multiple /3-subunit genes in many cases. Expression of a-subunit mRNA was found in each of the adenomas from patients expressing one of the /3-subunit mRNAs and in three patients with no detectable /3-subunit mRNA. Although FSHft and LH,6 mRNAs were found with similar frequencies in nonfunctioning adenomas, expression of FSH/3 mRNA was generally much more abundant. TSHft mRNA was detected in only one adenoma. The levels of glycoprotein hormone subunit mRNAs were variable in different adenomas, but the lengths of the mRNAs and transcriptional start sites for the a-and /3-subunit genes were the same in the pituitary adenomas and in normal pituitary. Growth hormone and prolactin gene expression were not observed in the nonfunctioning adenomas, but ACTH mRNA was found in a single case. Immunohistochemistry of the adenomas confirmed production of one or more pituitary hormones in 3/14 (93%) nonfunctioning tumors, with a distribution of hormone production similar to that of the hormone mRNAs. These data indicate that pituitary adenomas originating from cells producing glycoprotein hormones are common, but are difficult to recognize clinically because of the absence of characteristic endocrine syndromes and defective hormone biosynthesis and secretion.
Pituitary adenomas are classified according to characteristic clinical syndromes that result from excess secretion of hormones and by cellular phenotypes based upon immunohistochemistry or ultrastructure (1, 2) . The dramatic clinical manifestations of acromegaly and Cushing's disease led to the early recognition of excess growth hormone and ACTH secretion. Owing to the development of the prolactin immunoassay, a majority of chromophobe adenomas of previously unknown phenotype were shown to secrete prolactin (3). The identification of prolactin-secreting adenomas has been helpful in the selection of certain of these patients for treatment with bromocriptine (4). Despite these advances in diagnostic techniques, clinically nonfunctioning adenomas still constitute -25% of all pituitary tumors (2).
Although 15% ofcells in the normal pituitary gland produce luteinizing hormone (LH)', follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH) (5), pituitary adenomas secreting these hormones are diagnosed infrequently (6, 7) . With the exception of TSH-secreting adenomas, which can cause thyrotoxicosis (7), glycoprotein hormone-secreting adenomas do not result in characteristic endocrine syndromes and the detection of glycoprotein hormone-secreting adenomas using serum immunoassays is often difficult (6, 7) .
The glycoprotein hormones are heterodimers consisting of two different subunits called a and ,B. The a-subunit is common to all ofthe glycoprotein hormones and the unique /3-subunits confer biological and immunological specificity to the hormones (8) . Many glycoprotein hormone adenomas secrete uncombined and biologically inert a and/or /-subunits (6, 7) . Moreover, the excess production of uncombined a-subunit in TSH-producing adenomas has been used to distinguish adenomatous from nonadenomatous causes of inappropriate TSH secretion (7, 9) . In contrast to normals, many patients with gonadotropin-producing adenomas secrete FSH and LH in response to thyrotropin-releasing hormone (TRH) (6) . Interestingly, although FSH is released primarily as intact hormone, LH is secreted largely in the form of uncombined LH,3 subunit (6). These observations indicate that there are both biosynthetic and secretory defects in glycoprotein hormoneproducing adenomas and may explain, in part, the rare occurrence of endocrine manifestations by these tumors.
The availability of nucleic acid sequences encoding human ACTH (10) , growth hormone (1 1), prolactin (12) , the glycoprotein hormone common a-subunit (13) , and each of the glycoprotein hormone d-subunits (LHf [14] , FSHf3 [15] , and TSHf [16] (19) . The yield of total RNA was typically 1 ug RNA/mg of tumor. Expression of specific mRNAs were assessed by the Northern blot technique. After denaturation with glyoxal (20) , RNA was subjected to electrophoresis through 1.2% agarose gels, and electroeluted onto membranes (Genescreen Plus, New England Nuclear, Boston, MA). Ethidium bromide staining of the RNA before electrophoretic transfer showed no evidence of degradation. Membranes were hybridized with 32P-labeled oligonucleotides and washed as described previously (15 (15) .
SI -nuclease mapping of the transcriptional start sites of the glycoprotein hormone genes was performed as described previously (21) . 32P-labeled oligonucleotides (3, RNA prepared from normal pituitary, placenta, and the nonfunctioning pituitary adenomas was hybridized with cDNA probes specific for the mRNAs encoding a-subunit, prolactin, growth hormone, or ACTH (Fig. 1) . Hybridization of a-subunit mRNA, which is common to each of the pituitary glycoprotein hormones (TSH, LH, and FSH), was detected in normal pituitaries and in most of the pituitary adenomas. However, the levels of a-subunit mRNA were variable in adenomas from different patients (Fig. 1 A) . The same blot was rehybridized with prolactin-specific cDNA. Although abundant prolactin mRNA was found in normal pituitary tissue, none was detected in the nonfunctioning pituitary adenomas (Fig. 1 B) . Inasmuch as prolactin mRNA was abundant in the normal pituitary ( Fig. 1 B, lane pit) , these findings indicate that fragments of normal pituitary tissue do not account for the a-subunit mRNA observed in the pituitary adenomas. Similarly, growth hormone mRNA was absent from the nonfunctioning adenomas ( Fig. 1 C) , but was abundant in both normal pituitary tissue (Fig. 1 C, lane pit) and an adenoma from a patient with acromegaly (lane GH). ACTH mRNA was present in one of the pituitary adenomas (Fig. 1 D) , a finding consistent with (23) . The detection of prolactin ( Fig. 1 B, plac) and ACTH ( Fig. 1 D, plac) related mRNAs in placenta has been described previously (24, 25) . mentary to regions of the fl-subunit sequences with low homology were prepared for the TSHf3, FSHf3, LHfl, and CGf mRNAs (15) . Glycoprotein hormone fl-subunit mRNAs were detected in many of the clinically nonfunctioning adenomas (Fig. 2) . As occurs in normal pituitary (15) , the levels of fl-subunit mRNAs in most of the adenomas were lower than the levels of the a-subunit mRNA when hybridizing bands were compared using cDNAs of similar specific activity. Considerable variability existed in the levels of f-subunit mRNAs expressed in different adenomas and more than one glycoprotein hormone fl-subunit gene was expressed in some of the adenomas (Fig. 2, Table II ). For example, an adenoma (patient 2) in which high levels of a-subunit mRNA were observed (Fig. 1  A) also contained both FSH3 (Fig. 2 A) and LHf (Fig. 2 B) mRNAs.
Northern blot analyses showed no major differences in the lengths of the glycoprotein hormone a-or fl-subunit mRNAs expressed in the pituitary tumors and in normal pituitary tissue ( Figs. 1 and 2 ). S1-nuclease mapping was used to characterize the 5'-ends of the a and LHI3 mRNAs (21) and provided an independent method for analyses of gene expression in the nonfunctioning adenomas (Fig. 3) . Using an a-subunit-specific cDNA that overlaps the 5'-end of the a-subunit mRNA (21) , 29 of 36 bases of the labeled oligonucleotide were protected from S 1-nuclease digestion by hybridization to adenoma RNA (Fig. 3 A) . These findings confirmed that the hybridized mRNA (Fig. 1 A) was a-subunit mRNA and demonstrated that the transcriptional start site of the 'a-gene was identical in normal pituitary and in each of the pituitary adenomas that were studied. Similarly, the transcriptional start site of the LHfl gene in the adenomas and normal pituitaries was identical (Fig. 3 B) Expression of a-subunit nmRNA was found in all of the patients expressing one of the fl-subunit mRNAs and in three patients in whom no fl-subunit mRNA was found. In no case was glycoprotein hormone fl-subunit mRNA expressed in the absence of a-subunit mRNA. Patient 14 expressed a and CGfl mRNAs, consistent with ectopic expression ofthe CGB gene in a pituitary adenoma (17) . Although FSHfl and LHfl mRNAs were found with similar frequencies, expression of FSH3 mRNA was generally much more abundant. TSH3 mRNA was detected in only one patient.
Immunohistochemistry. Analysis of hormone production by immunohistochemistry indicated that the majority (86%) of the clinically nonfunctioning adenomas contain one or (Table II) 
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adenomas approaches that of Cushing's disease and acromegaly, but is less than that of prolactinomas (2). The cDNAs used for hybridization to pituitary mRNAs were highly specific, allowing distinction of related sequences such as prolactin (12) and growth hormone (11) , or the members of the glycoprotein hormone family (15) . Thus, in a somatotroph adenoma producing large amounts of growth hormone mRNA (Fig. 1 C, "GH" Although several adenomas contained a-subunit mRNA without immunostaining for free a-subunit, in each case there was immunostaining for the intact glycoprotein hormones in which the a-subunit is combined with 1-subunit. The prevalence of glycoprotein hormone immunostaining reported previously for nonfunctioning adenomas varies widely (27) (28) (29) (30) (31) , likely reflecting differences in fixation techniques or the sensitivities of different antisera. However, characterization of adenomas by analyses of gene expression and by immunohistochemistry in this study provides convincing evidence for the common occurrence of the glycoprotein hormone cell phenotype using independent techniques.
Although nonfunctioning adenomas express glycoprotein hormone genes and contain glycoprotein hormone antigens, it is unclear why excess hormone secretion is not observed more commonly in vivo. Effective glycoprotein hormone biosynthesis and secretion requires balanced expression of the a-and 13-subunit genes, translation of the mRNAs into proteins, complex posttranslational processing, and regulated secretion of the hormones (8) . Several lines of evidence indicate that glycoprotein hormone cell adenomas contain defects in one or more of these steps in hormone biosynthesis. The relative amounts of a-and 1-subunit mRNAs expressed in different pituitary adenomas varied widely. Furthermore, in comparison with normal pituitary and placenta, in which the levels of a-subunit mRNA were more abundant than 13-subunit mRNAs ( Figs. 1 and 2 ) (15), several adenomas (patients 1 and I 1) expressed relatively high levels of 1-subunit mRNA (Table   II) . One adenoma (patient 14), described previously in detail (17) , ectopically expressed a and CG1 mRNA, but did not produce hCG, suggesting a defect in the posttranslational processing or stability ofthe hormone. In addition to these abnormalities in glycoprotein hormone gene expression, previous studies have demonstrated secretion of uncombined a-and 1-subunits in both thyrotrope and gonadotrope-cell adenomas (6, 7, 32, 33) . Although electron microscopy was not performed on these adenomas, previous studies have demonstrated that nonfunctioning or null cell adenomas contain sparse secretory granules, consistent with ongoing hormone gene expression and biosynthesis. However, in addition to altered granule size and number, many of these adenomas contain other morphologic changes such as oncocytic changes and poorly developed cellular organelles (2, 28, 31 (34) (35) (36) (37) .
